• SIVA MADHU CHAITANYA Department of Pharmaceutical Analysis, KJR College of Pharmacy, Burugupudi, Andhra Pradesh, India
  • SRINATH NISSANKARARAO New York City Metropolitan Area, Montvale, New Jersey, USA 07645
  • SATYA LAKSHMI GANDHAM Department of Chemistry, Govt Degree College, Ganapavaram, Andhra Pradesh, India




Erlotinib, Ramucirumab, Development, Validation, NP-UPLC.


Objective: This investigation demonstrates a stability-indicating and reliable “normal phase ultra-performance liquid chromatography” method to simultaneously quantify Ramucirumab and Erlotinib in the pharmaceutical dosage form.

Methods: Successful separation was accomplished using Chiralcel-OD-3 column (50 mm x 4.6 mm, 3 μm) with isocratic type of elution using mobile phase containing n-hexane+isopropyl alcohol+methanol (89:10:1), respectively with 1.0 ml/min flow rate. The wavelength sensor was attuned at 266 nm to quantify Ramucirumab and Erlotinib.

Results: Erlotinib and Ramucirumab peaks were eluted with fine resolution at retention times 1.7807 min and 3.175min, respectively. In the 10-150 μg/ml and 1-15 μg/ml concentration ranges for Erlotinib and Ramucirumab, the calibration graphs were linear, with regression coefficients of 0.99928 and 0.99976, respectively. The suggested ultra-performance liquid chromatography approach has been shown as sensitive, precise, robust, accurate, specific and stability indicating through the resolution of Erlotinib and Ramucirumab from its degradation-based compounds.

Conclusion: The established ultra-performance liquid chromatography technique was effectively extended to the evaluation of Erlotinib and Ramucirumab in the pharmaceutical dosage form and the test results appeared satisfactory.


Download data is not yet available.


Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer 2011; 128:2020–30.

Siegel DL (January 2002). Recombinant monoclonal antibody technology. Transfusion Clinique et Biologique 2002; 9:15–22.

Ambrosi D, Mollica F. On the mechanics of a growing tumor. International Journal of Engineering Science 2002; 40:1297–316.

Amal H, Leja M, Funka K, Skapars R, Sivins A, Ancans G, et al. Detection of precancerous gastric lesions and gastric cancer through exhaled breath. Gut 2016; 65:400–7.

Qin J, Liu M, Ding Q, Ji X, Hao Y, Wu X, Xiong J. The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells. Molecular and Cellular Biochemistry 2014; 395:99–107.

Lenglinger J et al. The cardia: esophageal or gastric? Critical reviewing the anatomy and histopathology of the esophagogastric junction. Acta Chir Iugosl 2012; 59:15–26.

Bond-Smith G, Banga N, Hammond TM, Imber CJ. Pancreatic adenocarcinoma. BMJ (Clinical Research Ed.) 2012; 344:e2476.

Alfarouk KO, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int 2015; 15:71.

Goldman B. Multidrug resistance: can new drugs help chemotherapy score against cancer?. J Natl Cancer Inst 2003; 95:255–7.

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2015; 383:31–9.

Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res 2011; 17:5257–67.

Birbrair A, Zhang T, Wang ZM, Messi ML, Olson JD, Mintz A et al. Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Physiol Cell Physiol 2014; 307:C25-38.

Lee D, Kim D, Bin Choi Y, Kang K, Sung ES, Ahn JH, et al. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. mAbs 2016; 8:892–904.

Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 (3 Suppl):324S–339S.

Yang ZY, Liu L, Mao C, Wu XY, Huang YF, Hu XF, Tang JL. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. Cochrane Database Syst Rev 2014; CD009948.

Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB et al. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 2019; 322:438–44.

Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20:11142–59.

Bonaccorsi L, Muratori M, Carloni V, Marchiani S, Formigli L, Forti G, Baldi E. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells. Steroids 2004; 69:549–52.

Kim SW, Hayashi M, Lo JF, Yang Y, Yoo JS, Lee JD. ADP-ribosylation factor 4 small GTPase mediates epidermal growth factor receptor-dependent phospholipase D2 activation. J Biol Chem 2003; 278:2661–8.

Boyd MA, Menon P, Graves S, Gordon DL. A febrile illness with generalized papular rash involving the palms and soles. Clin Infect Dis 2007; 44:704,755–6.

DuPont HL. Acute infectious diarrhea in immunocompetent adults. N Engl J Med 2014; 370:1532–40.

Pavord ID, Chung KF. Management of chronic cough. Lancet 2008; 371: 1375–84.

Liao, Min-Tser, Sung, Chih-Chien, Hung, Kuo-Chin Wu, et al. Insulin Resistance in Patients with Chronic Kidney Disease. Journal of Biomedicine and Biotechnology 2012; 2012:1–5.

Sarin, Shiv Kumar, Choudhury, Ashok. Acute-on-chronic Liver Failure. Current Gastroenterology Reports 2016; 18:61.

Langell JT, Mulvihill SJ. Gastrointestinal perforation and the acute abdomen. Med Clin North Am 2008; 92:599–625.

Alhassan M.B, Rabiu M, Aqbabiaka I.O. Interventions for Mooren's ulcer. Cochrane Database Syst Rev 2014; 1:CD006131.

Osherov N, Gazit A, Gilon C, Levitzki A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J Biol Chem 1993; 268: 11134–42.

Anafi M, Gazit A, Zehavi A, Ben-Neriah Y, Levitzki A. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 1993; 82: 3524–9.

Shivani C.P, Maheshwari D. G, Development and validation of UV spectrometric and HPLC method for estimation of escitalopram oxalate and flupentixol dihydrochloride in combined dosage form. AJPTI 2016; 4: 59-70.

Supriya T, Naresh D, Vijaya Kumar G, Haneer MA. Stability indicating RP-HPLC method development and validation for simultaneous estimation of escitalopram and flupentixol pure and marketed formulation. Asian J Pharm Res 2018; 8: 4-10.

International conference on the harmonization. ICH harmonized tripartite guideline. Validation of analytical procedures: Text and methodology Q2(R1); 2005.

Vijayakumari M, Balasekhar reddy Ch. Stability indicating validated hplc method for the determination of zanubrutinib in bulk and pharmaceutical dosage form. Asian J Pharm Clin Res 2020; 13:159-62.

Rajakumari R, Sreenivasa Rao S et.al., Stress degradation studies and development of a validated RP-HPLC method for determination of Tiagabine in presence of its degradation products. Int J Pharm Pharm Sci 2016; 8:230-6.

Charu Pandya P, Sadhana Rajput J. Development and validation of stability indicating method RP-HPLC method of Acotiamide. Int J Pharm Pharm Sci 2018; 10:1-8.

Birva Athavia A, Zarna Dedania R et.al., Stability indicating HPLC method for determination of Vilazodone hydrochloride. Int J Curr Pharm Res 2017; 9:123-9.



How to Cite

CHAITANYA, S. M., NISSANKARARAO, S., & GANDHAM, S. L. (2021). A NEW NP-UPLC METHOD FOR THE SEPARATION AND SIMULTANEOUS QUANTIFICATION OF RAMUCIRUMAB AND ERLOTINIB. International Journal of Applied Pharmaceutics, 13(6). https://doi.org/10.22159/ijap.2021v13i6.42815



Original Article(s)